



## Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 1, 2021

AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: [STTK](#)), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC's 36<sup>th</sup> Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021.

### Presentation Details

Abstract Title: *Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer*

Abstract Number: 429

Presenter: Nehal J. Lakhani, MD, PhD, START Midwest

Date: November 12<sup>th</sup> - 14<sup>th</sup>

Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: *Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint (ARC) Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas*

Abstract Number: 494

Presenter: Melissa Johnson, MD, Sarah Cannon Research Institute

Date: November 12<sup>th</sup> - 14<sup>th</sup>

Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: *Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics That Stimulate Target Cells to Migrate from the Peripheral Blood*

Abstract Number: 3

Presenter: Louis Gonzalez, PhD, Shattuck's Director of Translational Research

Date: November 12<sup>th</sup> - 14<sup>th</sup>

Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Abstract Title: *LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-tumor Immunity in the Setting of PD-1 and TIGIT Checkpoint Blockade*

Abstract Number: 585

Presenter: George Fromm, PhD, Shattuck's Vice President of Research & Development

Date: November 12<sup>th</sup> - 14<sup>th</sup>

Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

Further information about the Society for Immunotherapy of Cancer Meeting can be found at:

<https://www.sitcancer.org/2021/home>

### About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC<sup>®</sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN<sup>™</sup>, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

### Investor Contact:

Conor Richardson

Senior Director, Finance & Investor Relations

Shattuck Labs, Inc.

[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

### Media Contact:

Stephanie Ascher

Managing Director

Stern Investor Relations, Inc.

[Stephanie.ascher@sternir.com](mailto:Stephanie.ascher@sternir.com)



Source: Shattuck Labs, Inc.